Both subgroups with an unmethylated MGMT promoter, MGMTmet−/MGMTlow and MGMTmet−/MGMThigh, had a higher tumor-related death probability irrespective of the MGMT protein expression (HR = 2.11 (95% CI: 0.92–4.83), p = 0.078 and HR = 3.78 (95% CI: 1.29–11.09), p = 0.015, respectively) compared to the MGMTmet+/MGMTlow patients. This evidence concerns the gene MGMT and neoplasm.